Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 6/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.48 |
| ▸ | AXL | P30530 | 5/20 | 0.48 |
| ▸ | NEK2 | P51955 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ULK1 | O75385 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.42 |
| ▸ | INSR | P06213 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2061451 | 0.88 | AXL (0.59) | ALKAXLNEK2IGF1RAURKA | |
| SCHEMBL30223453 | 0.88 | AXL (0.59) | ALKAXLNEK2IGF1RAURKA | |
| SCHEMBL29190691 | 0.86 | ALK (0.59) | ZAP70ALKIGF1RMEN1KMT2A | |
| SCHEMBL25551040 | 0.85 | AXL (0.48) | ALKAXLNEK2IGF1RAURKA | |
| SCHEMBL4095652 | 0.85 | IGF1R (0.50) | ZAP70ALKIGF1RMEN1KMT2A | |
| SCHEMBL375527 | 0.85 | IGF1R (0.50) | ZAP70ALKIGF1RMEN1KMT2A | |
| SCHEMBL13849367 | 0.84 | ZAP70 (0.58) | ZAP70ALKAXLNEK2IGF1R | |
| SCHEMBL375360 | 0.84 | ZAP70 (0.61) | ZAP70ALKAXLNEK2IGF1R | |
| SCHEMBL4103133 | 0.84 | IGF1R (0.49) | ZAP70ALKAXLIGF1RAURKA | |
| SCHEMBL29214361 | 0.83 | CDK7 (0.60) | ALKIGF1RAURKACDK7CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4137484-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | ZAP70 1786/4885ALK 82/4885AXL 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.